APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

• US 20140094471A1
• Filed: 09/26/2013
• Published: 04/03/2014
• Est. Priority Date: 05/26/2009
• Status: Active Grant

• Current Assignee: Abbvie Incorporated, Genentech, Inc. (Roche Holding AG), The Walter & Eliza Hall Institute Of Medical Research
• Original Assignee: Abbvie Incorporated, Genentech, Inc. (Roche Holding AG), The Walter & Eliza Hall Institute Of Medical Research
• Inventors: Bruncko, Milan, Ding, Hong, Doherty, George A., Elmore, Steven W., Hasvold, Lisa A., Hexamer, Laura, Kunzer, Aaron R., Song, Xiaohong, Souers, Andrew J., Sullivan, Gerard M., Tao, Zhi-Fu, Wang, Gary T., Wang, Le, Wang, Xilu, Wendt, Michael D., Mantei, Robert A., Hansen, Todd M.
• Granted Patent: US 9,174,982 B2
• Time in Patent Office: Days
• US Class Current: 514/253.04
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 209/82 Carbazoles; Hydrogenated carbazoles
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 519/00 Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Claims

1-30. -30. (canceled)

31. A method of treating cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound having Formula (I)

32. (canceled)